Ironwood Pharmaceuticals (IRWD) Receives Notice Of Allowance For Methods Of Use Formulation Patent Expected To Extend LINZESS® Patent Protection Through 2031
2/10/2014 9:52:27 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application covering methods of using LINZESS® (linaclotide) to treat patients with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). The patent application, co-owned by Ironwood and Forest Laboratories, Inc., is expected to issue in mid-2014 and extend LINZESS patent protection into 2031.
Help employers find you! Check out all the jobs and post your resume.
comments powered by